How to Reconstitute MOTS-c: Syringe Selection and Needle Gauge Guide

What Is MOTS-c and Why Does Reconstitution Precision Matter?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondria-derived peptide first characterized by Lee et al. In 2015. Published in Cell Metabolism, that paper showed MOTS-c activates the AMPK pathway, improves insulin sensitivity, and reduces obesity in mouse models fed a high-fat diet [1]. Because it is supplied as a lyophilized (freeze-dried) powder, every variable in reconstitution, including diluent choice, volume, and injection hardware, directly affects the dose you receive per unit drawn.

Peptide degradation is a real concern. Research on short peptide stability confirms that incorrect diluents, temperature excursions, or repeated freeze-thaw cycles accelerate hydrolysis and aggregation [2]. A 5% error in reconstitution volume produces a 5% dosing error on every subsequent injection, compounding across a multi-week cycle.

Why MOTS-c Differs from Standard Peptides

At 16 amino acids and roughly 2.1 kDa, MOTS-c is smaller than most research peptides like BPC-157 (15 aa) or ipamorelin (5 aa). Smaller peptides tend to be more soluble but also more susceptible to oxidation at methionine residues. USP <1> general notices specify that sterile preparations must use validated diluents and containers to preserve both sterility and chemical stability [3].

Regulatory Context

MOTS-c is not FDA-approved as a drug product. It is available through 503B outsourcing facilities and compounding pharmacies operating under FDA oversight. The FDA's guidance on compounded drug products under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act governs its preparation standards [4]. Clinicians prescribing or supervising MOTS-c use should verify their compounding pharmacy holds current registration and follows Current Good Manufacturing Practice (cGMP) standards.

Choosing the Right Diluent: Bacteriostatic Water vs. Sterile Water

Bacteriostatic water for injection is the standard diluent for MOTS-c. The 0.9% benzyl alcohol preservative in BWFI inhibits microbial growth across the 20 to 30 day use window of a multi-dose vial [5]. Sterile water for injection (SWFI) contains no preservative and becomes a single-use diluent the moment it enters the vial, any remaining solution must be discarded immediately, making it impractical for clinical dosing protocols.

How Benzyl Alcohol Preserves the Reconstituted Solution

Benzyl alcohol works as a bacteriostatic agent at 0.9% concentration by disrupting bacterial cell membranes. The USP monograph for bacteriostatic water for injection specifies this concentration and mandates that BWFI passes the Antimicrobial Effectiveness Test described in USP <51> [3]. For multi-dose peptide vials used over days to weeks, this preservative activity is not optional, it is the primary defense against contamination from repeated needle entry.

Normal Saline as an Alternative

Bacteriostatic normal saline (0.9% NaCl with 0.9% benzyl alcohol) is occasionally used when researchers are concerned about osmolality matching. For subcutaneous peptide injections, the volume injected (typically 0.05 to 0.2 mL) is small enough that the tonicity difference between BWFI and bacteriostatic saline is clinically negligible. Both are acceptable diluents for MOTS-c [5].

What to Avoid

Never use tap water, distilled water, or reconstituted solutions from non-sterile vials. Do not use BWFI in neonates, the FDA issued a specific warning that benzyl alcohol toxicity has caused fatal gasping syndrome in premature and low-birthweight infants [6]. This warning does not apply to adult subcutaneous use, but it is the reason some institutional protocols specify SWFI even for adults.

Reconstitution Volume and Working Concentration

The most common MOTS-c vial size in compounding is 10 mg. Adding 1 mL of BWFI produces a 10 mg/mL (10,000 mcg/mL) solution. Adding 2 mL produces 5 mg/mL (5,000 mcg/mL). The choice depends on the prescribed daily dose and the syringe volume you will use.

The Dosing Math

Most clinical protocols for MOTS-c in metabolic health contexts target 5 to 15 mg per injection, administered subcutaneously, based on early human-use data extrapolated from the mouse pharmacology reported by Lee et al. [1] and later extended in aging research by Reynolds et al., who showed MOTS-c improves physical performance and insulin sensitivity in older adults in a small pilot study [7].

Use this formula to calculate draw volume:

Draw volume (mL) = Prescribed dose (mg) / Working concentration (mg/mL)

For a 10 mg dose from a 10 mg/mL vial: 10 mg / 10 mg/mL = 1.0 mL. That exceeds the barrel of a 0.5 mL insulin syringe, so either use a 1 mL syringe or reconstitute to 5 mg/mL (add 2 mL BWFI), giving a draw of 0.2 mL per 10 mg dose. This is the more practical option for subcutaneous self-injection.

Concentration Table

| Vial Size | BWFI Added | Concentration | Dose 5 mg | Dose 10 mg | |-----------|-----------|---------------|-----------|------------| | 10 mg | 1 mL | 10 mg/mL | 0.05 mL (5 units U-100) | 0.10 mL (10 units U-100) | | 10 mg | 2 mL | 5 mg/mL | 0.10 mL (10 units U-100) | 0.20 mL (20 units U-100) | | 10 mg | 4 mL | 2.5 mg/mL | 0.20 mL (20 units U-100) | 0.40 mL (40 units U-100) |

The 10 mg/mL concentration paired with a 0.3 mL (30-unit) U-100 insulin syringe covers doses up to 3 mg with excellent precision. For doses of 5 to 10 mg, the 5 mg/mL concentration in a 0.5 mL (50-unit) syringe is the standard clinical setup.

Syringe Selection for MOTS-c Subcutaneous Injection

U-100 insulin syringes are the gold-standard delivery device for subcutaneous peptide injections. The U-100 designation means each milliliter is divided into 100 units on the barrel, giving 0.01 mL resolution. At a working concentration of 5 mg/mL, each U-100 unit equals 0.05 mg of MOTS-c, a level of precision that a standard 1 mL Luer-lock syringe cannot match [8].

Barrel Size Options

Three barrel sizes are available for U-100 insulin syringes:

• 0.3 mL (30 units): Best for doses <3 mg at 10 mg/mL. Smallest dead-space volume, highest precision.
• 0.5 mL (50 units): Best for doses of 2.5 to 5 mg at 10 mg/mL or 5 to 10 mg at 5 mg/mL. The most commonly dispensed size for MOTS-c.
• 1.0 mL (100 units): Needed for doses >5 mg at 10 mg/mL. Slightly less precision per unit mark.

The American Diabetes Association standards of care recommend 0.3 mL and 0.5 mL syringes for self-injection because the shorter barrel reduces grip fatigue and improves dose accuracy at small volumes [9].

Fixed-Needle vs. Removable-Needle Syringes

Fixed-needle syringes (where the needle is permanently attached) have lower dead-space volume, sometimes as low as 0.5 mcL compared with 7 to 10 mcL for standard Luer-lock syringes. For peptide dosing where every microgram counts, fixed-needle U-100 syringes are preferred [8]. Brands such as BD Ultra-Fine and Terumo SurGuard3 are widely available at compounding pharmacies.

Needle Gauge and Length for MOTS-c

Gauge Selection

Needle gauge is inversely proportional to bore diameter. For subcutaneous peptide injection, the clinical target range is 28 to 31 gauge:

• 28 G: Slightly faster flow, useful when draw volume exceeds 0.3 mL. Minimal pain increase vs. 29 G.
• 29 G: The most common clinical choice. Validated for insulin and peptide subcutaneous delivery in multiple pharmacokinetic studies [10].
• 30 G: Preferred by patients with needle anxiety. Flow rate is adequate for aqueous peptide solutions at typical volumes.
• 31 G: Standard on BD Ultra-Fine II short-pen needles. Appropriate for volumes <0.2 mL.

Gauges coarser than 27 G (e.g., 25 G) produce unnecessary tissue trauma and are never indicated for subcutaneous peptide use. Gauges finer than 32 G risk needle deflection in subcutaneous fat, which can alter the injection depth.

Needle Length Selection

Subcutaneous tissue depth varies by body site and adiposity. A 2014 ultrasound study of 388 patients published in Diabetes Care found median subcutaneous fat depth at the abdomen was 17.5 mm in patients with BMI >25, but as low as 6 mm at the lateral thigh [11]. Based on this anatomy:

• 5/16 inch (8 mm): The standard for abdominal and lateral thigh subcutaneous injections in most adults. Reaches subcutaneous fat without penetrating muscle in individuals with BMI >20.
• 1/4 inch (6 mm): Appropriate for lean individuals or lateral thigh sites where subcutaneous depth is <8 mm.
• 1/2 inch (12.7 mm): Avoid for MOTS-c. At this length, intramuscular injection is likely in lean individuals, altering absorption kinetics.

The CDC's immunization guidelines similarly recommend 5/8 inch maximum for subcutaneous injections in adults, confirming that 8 mm needles keep delivery reliably in subcutaneous tissue [12].

Step-by-Step Reconstitution Protocol

Materials Checklist

Before you begin, gather: lyophilized MOTS-c vial, BWFI vial, two alcohol swabs (70% isopropyl), the appropriate insulin syringe, a clean dry surface, and a sharps container. Wash hands with soap for 20 seconds before handling any vial.

Reconstitution Steps

1. Swab the rubber septa of both vials with separate alcohol swabs. Allow 30 seconds of air-dry time. Wet alcohol on the septum can carry surface contamination into the vial on needle entry.
2. Draw back the plunger to your target BWFI volume (e.g., 2 mL). Insert the needle into the BWFI vial at a 45° angle and allow the negative pressure to pull diluent in, or gently pull the plunger to fill.
3. Insert the needle into the MOTS-c lyophilizate vial and inject the BWFI slowly down the inside wall of the vial. Do not aim the stream directly at the lyophilized cake, this can cause foaming and peptide denaturation [2].
4. Swirl gently for 15 to 30 seconds. Do not shake. Vortexing creates air bubbles and mechanical shear that can disrupt peptide secondary structure [2].
5. Inspect for clarity. A properly reconstituted MOTS-c solution is colorless to very pale yellow and free of particulate matter. Cloudy or particulate solutions must be discarded per USP <1> general standards [3].
6. Label the vial with date, concentration, and expiry (reconstitution date + 30 days).

Drawing the Dose

Insert a fresh insulin syringe needle through the reconstituted vial septum. Invert the vial. Draw slightly past your target volume, then slowly push back to the exact unit mark, expelling any air bubble. This back-and-fill technique is standard in insulin dosing education from the ADA [9] and applies equally to peptide injections.

Injection Sites and Subcutaneous Technique

Site Selection

The abdomen (at least 2 inches from the navel) and the lateral thigh are the two primary sites for MOTS-c subcutaneous injection. The upper outer buttock is a secondary option. Rotate sites with every injection to prevent lipohypertrophy, which impairs absorption. A study in Diabetes Care demonstrated that injecting into hypertrophied tissue reduces insulin bioavailability by up to 25% [13], an analogous effect is expected for peptide absorption.

Injection Angle

At 8 mm needle length, inject at a 90° angle into an unpinched skin fold in individuals with adequate subcutaneous fat (BMI >22). Lean individuals should pinch a skin fold and inject at 45° to avoid intramuscular placement. USP <1> general requirements for injections note that intramuscular delivery of preparations formulated for subcutaneous use alters intended pharmacokinetics [3].

Post-Injection

Do not rub the injection site. Rubbing increases local blood flow and may accelerate peptide absorption unevenly. Apply light pressure with a clean gauze if a small bleed occurs. Recap the needle using a one-handed scoop technique and dispose in a certified sharps container per EPA sharps waste guidelines [14].

Storage, Stability, and Handling

Lyophilized MOTS-c vials store at 2 to 8 °C (standard refrigerator temperature). If storage beyond six months is anticipated, freezing at -20 °C is acceptable for most lyophilized peptides provided the vial is thawed only once before use [2]. Repeated freeze-thaw cycles introduce ice crystal shear stress that fragments peptide chains.

Once reconstituted with BWFI, store at 2 to 8 °C. Do not freeze the reconstituted solution. BWFI's benzyl alcohol preservative is effective at refrigerator temperature but may not prevent all microbial growth at room temperature over extended periods [5]. Discard any vial left at room temperature for more than four hours.

The 30-day discard window for BWFI-reconstituted peptides is derived from USP <797> compounding standards for low-risk multi-dose preparations [15]. Some compounding pharmacies apply more conservative 14-day windows, follow the beyond-use date printed on your specific vial label.

Common Reconstitution Errors and How to Avoid Them

Error 1: Using Too Little Diluent

Adding only 0.5 mL to a 10 mg vial creates a 20 mg/mL solution. At this concentration, drawing a 10 mg dose requires only 0.05 mL (5 units on a U-100 syringe). Small errors in reading the syringe scale become large percentage dosing errors. A 1-unit misread equals a 20% dose error. Diluting to 5 mg/mL or lower improves measurement precision [8].

Error 2: Shaking the Vial

Shaking introduces mechanical shear. For peptides with amphiphilic regions, shearing promotes aggregation into insoluble fibrils. Peptide aggregation in parenteral preparations is a recognized pharmaceutical concern documented in FDA guidance on immunogenicity of therapeutic proteins [16]. MOTS-c is not a biologic in the regulatory sense, but the same physical chemistry applies to its short peptide chain.

Error 3: Injecting Cold Reconstituted Solution

Cold solutions (<10 °C) increase injection-site discomfort and may cause local vasoconstriction. Allow the drawn syringe to reach room temperature over 5 to 10 minutes before injecting. Do not use a microwave or warm water bath, uneven heating can exceed 40 °C at local points and accelerate peptide hydrolysis [2].

Error 4: Reusing Needles

A single-use needle dulls measurably after one skin puncture. Electron microscopy studies have documented hook formation and barb development on 28 to 31 G needles after a single use [17]. Reusing needles increases injection pain, risk of coring the rubber septum, and contamination risk from skin flora.

MOTS-c Dosing Context: What the Clinical Evidence Shows

MOTS-c research in humans remains early-stage. The most cited human pilot was Reynolds et al., a 4-week randomized controlled trial (N=40 older adults, mean age 72.6 years) that used MOTS-c 2 mg/kg subcutaneously three times per week and showed improved insulin sensitivity (HOMA-IR decreased 18.3% vs. Placebo, P<0.05) and increased skeletal muscle mitochondrial activity measured by 31P-MRS [7]. Body weight did not differ significantly between groups over four weeks.

The foundational mechanistic work by Lee et al. In Cell Metabolism (2015) demonstrated that exogenous MOTS-c at 15 mg/kg/day in mice prevented diet-induced obesity and improved glucose tolerance without altering food intake, implicating AMPK-FOXO1 signaling as the primary pathway [1]. Extrapolating mouse mg/kg doses to human equivalents using body surface area scaling (FDA guidance Estimating the Maximum Safe Starting Dose) produces an estimated human equivalent dose of approximately 1.2 mg/kg, which aligns with the doses used in early pilot human studies [18].

These data inform clinical decision-making but do not constitute FDA-approved dosing. Clinicians supervising MOTS-c use should document their clinical rationale, obtain informed consent, and monitor fasting glucose, insulin, and basic metabolic panel at baseline and every 30 days.